Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2014, vol. 23, nr 5, September-October, p. 827–834

Publication type: original article

Language: English

Expression and Interactions Between Cell Adhesion Molecules CD44v6 and E-Cadherin in Human Gliomas

Julia K. Bar1,A,C,D,F, Lesław Zub2,B,E,G, Anna Lis-Nawara1,B,D,G, Leszek Noga3,C,E,G, Michał Jeleń1,E,F, Bogusław Paradowski4,B,E,F,G

1 Department of Pathomorphology and Oncological Cytology, Wroclaw Medical University, Poland

2 Department of Neurosurgery, Wroclaw Medical University, Poland

3 Department of Pathophysiology, Wroclaw Medical University, Poland

4 Department of Neurology, Wroclaw Medical University, Poland

Abstract

Background. Gliomas are a heterogenous group of tumors that show the same histological features but differ in their behavior. Gliomas are characterized by biological aggressiveness and extensive infiltrative growth into surrounding healthy brain tissue.
Objectives. . In this study we estimated CD44v6 and E-cadherin expression and correlation between CD44v6 and E-cadherin in relation to glioma malignancy. We also analyzed simultaneous expression of CD44v6 and E-cadherin in the same tumor sample in order to determine the biological tumor behavior.
Material and Methods. Expression of CD44v6 and E-cadherin was evaluated on ninety-two formalin-fixed paraffin-embedded glioma tissue blocks using immunohistochemistry (IHC).
Results. CD44v6 expression was found in 71.6% of gliomas. There was a statistically significant difference between the frequency of positive cases for CD44v6 expression in low (grade I) vs. high (grade IV) as well as in grade I vs. grade II of glioma malignancy (p = 0.001). E-cadherin membrane staining was observed in 28.8% of gliomas. No significant differences were observed between E-cadherin expression and grade of gliomas (p > 0.05). However, re-expression of E-cadherin was found in grade II gliomas. In this group, E-cadherin expression was revealed in 43.3% of the cases. In order to define the relationship between CD44v6 expression and E-cadherin, we analyzed the simultaneous expression of CD44v6 and E-cadherin in the same glioma sample in the whole group and in respect to the degree of glioma malignancy. A positive correlation between studied biomarkers was observed in the analyzed gliomas (p = 0.004) but a simultaneous expression of CD44v6 and E-cadherin revealed no significant differences in respect to glioma malignancy.
Conclusion. Our results showed that the level of E-cadherin might reflect different biological features of gliomas, whereas CD44v6 is associated with tumor cell malignancy. The simultaneous presence of CD44v6 and E-cadherin in a set of low-grade gliomas indicates that both these molecules might strengthen cell migration and may be a hallmark of glioma invasive growth.

Key words

gliomas, CD44v6, E-cadherin, immunohistochemistry.

References (28)

  1. Nager M, Bhardwaj D, Canti C, Medina L, Nogues P, Herreros J: β-catenin signalling in glioblastoma multiforme and glioma-initiating cells. Chemother Res Pract 2012, ID 192362, doi:1155/2012/192362.
  2. Wang M, Wang T, Liu Sh, Yoshid D, Teramoto A: The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 2003, 20, 65–72.
  3. Holland EC: Glioblastoma multiforme; the terminator. PNAS 2000, 97, 6242–6244.
  4. Lewis-Tuffin LJ, Rodriguez F, Giannini C, Scheithauer B, Necela BM, Sarkaria JN, Anastasiadis PZ: Misregulated E-cadherin expression associated with an aggressive brain tumor phenotype. PLoS ONE 2010, 5, e13665, doi:10.1371/journal.pone.0013665
  5. Ulrich TA, Pardo J, Kumar EM: Mechanical rigidity of the extracellular matrix regulates the structure, motility, and proliferation of glioma cells. Cancer Res 2009, 69, 4167–4174.
  6. Kim Ch-S, Jung Sh, Jung T-Y, Jang W-Y, Sun H-S, Ryu H-H: Characterization of invading glioma cells using molecular analysis of leading-edge tissue. J Korean Neurosurg Soc 2011, 50, 157–165.
  7. Xu Y, Stamenkovic I, Yu Q: CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res 2010, 70, 2455–2564.
  8. Jijiwa M, Demir H, Gupta S, Leung C, Joshi K, Orozco N, Huang T, Yildiz VO, Shibahara I, Jesus JA, Yong WH, Mischel PS, Fernandez S, Kornblum HI, Nakano I: CD44v6 regulates growth of brain tumor stem cells partially through the AKT-mediated pathway. PLoS ONE 2011, 6, e 24217,doi:10.1371/journal.pone.0024217.
  9. Jung T, Gross W, Zoller M: CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 2011, 18, 15862–15874.
  10. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Heijden M: Inhibition of notch signaling in glioblastoma targets cancer stem cell via an endothelial cell intermediate. Stem Cells 2010, 28, 1019–1029.
  11. Brown RL, Reinke I.M, Damerow MS, Perez D, Chodosh LA, Yang I, Cheng C: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Inv 2011, 3, 1064–1074.
  12. Lee JL, Wang MJ, Sudhir PR, Chen GD, Chi CW, Chen IY: Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res 2007, 67, 2089–2097.
  13. Dimov I, Tasić-Dimov D, Conić I, Stefanovic V: Glioblastoma multiforme stem cells. Scientific World Journal 2011, 11, 930–958.
  14. Wells A, Yates C, Shepard ChR: E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 2008, 25, 621–628.
  15. Howng SL, Wu CH, Cheng TS, Sy WD, Lin PC, Wang C, Hong YR: Differential expression of Wnt genes, betacatenin and E-cadherin in human brain tumors. Cancer Lett 2002, 183, 95–101.
  16. Motta FJN, Valera ET, Lucio-Eterovic AKB, Queiroz RGP, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, Marie SKN, Tone LG: Differential expression of E-cadherin gene in human neuroepithelial tumors. Genet Mol Res 2008, 7, 295–304.
  17. Xia M, Xu M, Wang J, Xu Y, Chen X. Ma Y, Su L: Identification of the role of Smad interacting protein 1 (SIP1) in glioma. J Neurooncol 2010, 97, 225–232.
  18. Kaur H, Phillips-Mason PJ, Burden-Gulley SM, Kerstetter-Forgle AE, Basilion JP, Sloan AE, Brady-Kalnay SM: Cadherin 11, a marker of the mesenchymal phenotype, regulates glioblastoma cell migration and survival in vivo. Mol Cancer Res 2012, 3, 293–304.
  19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO classification of tumours of the central nervous system. Lyon, France, International Agency for Research on Cancer (IARC), 2007, 4rd Ed., 14–33.
  20. Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko JV, Hamada JI: Aberrant signaling pathways in glioma. Cancers 2011, 3, 3242–3278.
  21. David JM, Rajasekaran AK: Dishonorable Discharge: The oncogenic roles of cleaved E-cadherin fragments. Cancer Res 2012, 72, doi:10.1158/008-5472.CAN-11-3498.
  22. Gun BD, Bahadir B, Bektas S, Barut F, Yurdakan G, Kandemir NO, Ozdamar SO: Clinicopathological significance of fascin and CD44v6 expression in endometrioid carcinoma. Diag Pathol 2012, 7, 80, http://www.diagnosticpathology. org/content/7/1/80.
  23. Deng Z, Niu G, Cai L, Wei R, Zhao X: The prognostic significance of CD44v6, CDH11, and β-catenin expression in patients with osteosarcoma. BioMed Res Int 2013, http://dx.doi.org/10.1155/2013/496193.
  24. Salech F, Reno W: Invasive cribriform breast carcinomas in patients with grade I and stage IIA (T2 N0 MO) breast cancer strongly express the v3 and v6, but not v4 isoforms of metastatic marker CD44. Neoplasma 2008, 55, 246–255.
  25. Keysar SB, Jimeno A: More than markers: biological significance of cancer stem cell-defining molecules. Mol Cancer Ther 2010, 9, 2450–2457.
  26. Rodriguez FJ, Lewis-Tuffin LJ, Anastasiadis PZ: E-cadherin’s dark side: possible role in tumor progression. Bioch Bioph Acta 2012, 1826, 23–31.
  27. Kim YD, Joo JK, Park YK, Ryu SY, Kim, HS, Noh BK, Lee KH: E-cadherin expression in early gastric carcinoma and correlation with lymph node metastasis. J Surg Oncol 2007, 96, 429–435.
  28. Thiery JP, Seleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Mol Cell Biol 2006, 7, 131–142.
© Wroclaw Medical University